Let me tell you, folks, we’ve got something incredible here with the PHERGain trial. It’s huge, really huge. We’re talking about a game-changer in the fight against breast cancer. You know, the kind that’s HER2-positive, invasive, and operable. We’ve got this amazing tool, the [¹⁸F]FDG PET/CT, and believe me, it’s fantastic. It’s like a crystal ball, showing us who really needs the heavy-duty chemotherapy and who doesn’t.

So, here’s the deal: we gave these patients, a lot of them, 227 out of 285, to be exact, a couple of cycles of this top-notch treatment, trastuzumab and pertuzumab, sometimes throwing in endocrine therapy. And guess what? 80% of them responded. That’s right, their cancer basically started waving the white flag. But we didn’t stop there. We wanted to know the best way to predict who’s going to beat this thing completely, without a trace left.

And we found it. The magic number? A 77% reduction in SUV_max. If you hit that, your chances of knocking out cancer completely jump up to 59.5%. That’s right, nearly 60%. And here’s the kicker: with this new cutoff, we can potentially spare a bunch of patients from the ordeal of chemotherapy. We’re talking about a significant number of people keeping their quality of life while fighting cancer. It’s incredible.

But, let’s not forget, the original plan, with a 40% reduction, it’s still solid. It maximizes the number of patients who could skip the chemo. So, we’ve got options. That’s what this trial is all about – giving people options, hope, and a real shot at beating cancer with less suffering. It’s a big win, folks, a really big win for everyone involved.